Copyright © 2010 American Medical Association. All rights reserved. From: Detecting Acute Human Immunodeficiency Virus Infection Using 3 Different Screening Immunoassays and Nucleic Acid Amplification Testing for Human Immunodeficiency Virus RNA, 2006-2008 Arch Intern Med. 2010;170(1):66-74. doi:10.1001/archinternmed.2009.445 Figure Legend: Window of detection of human immunodeficiency virus (HIV) markers early in HIV infection and window period of different enzyme immunoassays compared with nucleic acid amplification testing (NAAT) for HIV RNA. EIA indicates enzyme immunoassay. Data from Fiebig et al; the figure was adapted from a graphic courtesy of Steven Kleinman, MD. Date of download: 10/4/2017 Copyright © 2010 American Medical Association. All rights reserved.

Copyright © 2010 American Medical Association. All rights reserved. From: Detecting Acute Human Immunodeficiency Virus Infection Using 3 Different Screening Immunoassays and Nucleic Acid Amplification Testing for Human Immunodeficiency Virus RNA, 2006-2008 Arch Intern Med. 2010;170(1):66-74. doi:10.1001/archinternmed.2009.445 Figure Legend: Human immunodeficiency virus (HIV) screening algorithm with pooled nucleic acid amplification testing (NAAT) for the Centers for Disease Control and Prevention Acute HIV Infection Study, 2006-2008. EIA indicates enzyme immunoassay. The proprietary information on the EIAs and APTIMA HIV-1 Assay is given in the “Testing Protocol” subsection of the “Methods” section. *Positive pools and individual specimens underwent testing in duplicate for suspected acute/primary HIV infection. †Persons with specimens with positive NAAT results but an undetectable viral load underwent follow-up testing to resolve discrepant results. Date of download: 10/4/2017 Copyright © 2010 American Medical Association. All rights reserved.